Back to News
Market Impact: 0.12
Aptar Pharma and Macquarie University Collaborate to Advance Inhaled Biologics Through Australian Research Council-Supported Program
Source: Business Wire
Healthcare & BiotechTechnology & InnovationProduct Launches
Aptar Pharma and Macquarie University launched ARC-supported research to advance inhaled biologics using Aptar's Orbital™ dry-powder inhaler platform. The collaboration signals continued development activity in inhaled drug-delivery technology, but no financial terms, clinical results, or commercialization timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Microsoft gives Copilot a much-needed overhaul, and the stock deservedly soars
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk